Idorsia Ltd (IDRSF)
OTCMKTS · Delayed Price · Currency is USD
3.500
-0.090 (-2.51%)
At close: Aug 7, 2025
Idorsia Revenue
Idorsia had revenue of 72.24M CHF in the quarter ending June 30, 2025, with 341.89% growth. This brings the company's revenue in the last twelve months to 217.22M, up 69.92% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
217.22M CHF
Revenue Growth
+69.92%
P/S Ratio
2.51
Revenue / Employee
334.19K CHF
Employees
650
Market Cap
685.66M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Glass House Brands | 221.55M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Idorsia News
- 5 days ago - Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire
- 13 days ago - Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire
- 24 days ago - Idorsia Ltd (IDRSF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Idorsia Ltd 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 25 days ago - Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results - GlobeNewsWire
- 4 weeks ago - Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta - GlobeNewsWire
- 7 weeks ago - A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans - GlobeNewsWire
- 2 months ago - Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire